What do systematic reviews say?

Omega‐3 vs placebo

• Omega‐3 fatty acid supplementation for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 29 participants
  Very low

Fatty acid supplementation vs placebo compared with improving child growth and development for

• Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 187 participants
  Moderate

Fatty acid supplementation vs placebo compared with improving child growth and development for

• Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 238 participants
  Low

Fatty acid supplementation vs placebo compared with improving child growth and development for

• Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 113 participants
  Low

Fatty acid supplementation vs placebo compared with improving child growth and development for

• Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 110 participants
  Low

Fatty acid supplementation vs placebo compared with improving child growth and development for

• Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 111 participants
  Low

Fatty acid supplementation vs placebo compared with improving child growth and development for

• Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 414 participants
  Moderate

Omega‐3 vs placebo

• Omega‐3 fatty acid supplementation for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Very low

Omega‐3 vs placebo

It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes adverse events: diarrhoea compared with placebo (very low certainty).

• Omega‐3 fatty acid supplementation for cystic fibrosis 2020 · Cochrane Headline outcomes only
  OR 0.6 [0.05, 6.79]
  1 study · 12 participants
  Very low

Omega‐3 vs placebo

It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FEV1 % predicted compared with placebo (very low certainty).

• Omega‐3 fatty acid supplementation for cystic fibrosis 2020 · Cochrane Headline outcomes only
  MD 2 [19.11, 23.11]
  1 study · 17 participants
  Very low

Omega‐3 vs placebo

It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FVC % predicted compared with placebo (very low certainty).

• Omega‐3 fatty acid supplementation for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

Omega‐3 vs placebo

It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes growth and nutrition: BMI SD score compared with placebo (very low certainty).

• Omega‐3 fatty acid supplementation for cystic fibrosis 2020 · Cochrane Headline outcomes only
  MD 0
  1 study · 29 participants
  Very low

Intervention not reported

The intervention may leads to higher polyunsaturated fatty acids(5 trials; 252 participants) (low certainty).

• Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 4.44 [2.4, 8.48]
  Studies not reported
  Low

Intervention not reported

It is very uncertain whether the intervention changes polyunsaturated fatty acids(2 RCTs; 252 participants) (very low certainty).

• Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  Rate ratio 0.9 [0.68, 1.21]
  Studies not reported
  Very low

Intervention not reported

• Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

It is very uncertain whether the intervention changes amino acids(2 RCT; 152 participants) (very low certainty).

• Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 0.61 [0.28, 1.28]
  Studies not reported
  Very low

Intervention not reported

It is very uncertain whether the intervention changes amino acids + vitamin C(1 RCT; 191 participants) (very low certainty).

• Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.76 [0.62, 5.53]
  Studies not reported
  Very low

Intervention not reported

It is very uncertain whether the intervention changes amino acids(1 RCT; 78 participants) (very low certainty).

• Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  Rate ratio 0.81 [0.42, 1.54]
  Studies not reported
  Very low